Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.

<h4>Aims</h4>Controversy exists in regard to the beneficial effects of transplanting cardiac or somatic progenitor cells upon myocardial injury. We have therefore investigated the functional short- and long-term consequences after intramyocardial transplantation of these cell types in a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leonie E Paulis, Alexandra M Klein, Alexander Ghanem, Tessa Geelen, Bram F Coolen, Martin Breitbach, Katrin Zimmermann, Klaas Nicolay, Bernd K Fleischmann, Wilhelm Roell, Gustav J Strijkers
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eadcfda88b0e480e92d06df2a1ab06c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eadcfda88b0e480e92d06df2a1ab06c2
record_format	dspace
spelling	oai:doaj.org-article:eadcfda88b0e480e92d06df2a1ab06c22021-11-18T07:49:57ZEmbryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.1932-620310.1371/journal.pone.0061510https://doaj.org/article/eadcfda88b0e480e92d06df2a1ab06c22013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23585908/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aims</h4>Controversy exists in regard to the beneficial effects of transplanting cardiac or somatic progenitor cells upon myocardial injury. We have therefore investigated the functional short- and long-term consequences after intramyocardial transplantation of these cell types in a murine lesion model.<h4>Methods and results</h4>Myocardial infarction (MI) was induced in mice (n = 75), followed by the intramyocardial injection of 1-2×10(5) luciferase- and GFP-expressing embryonic cardiomyocytes (eCMs), skeletal myoblasts (SMs), mesenchymal stem cells (MSCs) or medium into the infarct. Non-treated healthy mice (n = 6) served as controls. Bioluminescence and fluorescence imaging confirmed the engraftment and survival of the cells up to seven weeks postoperatively. After two weeks MRI was performed, which showed that infarct volume was significantly decreased by eCMs only (14.8±2.2% MI+eCM vs. 26.7±1.6% MI). Left ventricular dilation was significantly decreased by transplantation of any cell type, but most efficiently by eCMs. Moreover, eCM treatment increased the ejection fraction and cardiac output significantly to 33.4±2.2% and 22.3±1.2 ml/min. In addition, this cell type exclusively and significantly increased the end-systolic wall thickness in the infarct center and borders and raised the wall thickening in the infarct borders. Repetitive echocardiography examinations at later time points confirmed that these beneficial effects were accompanied by better survival rates.<h4>Conclusion</h4>Cellular cardiomyoplasty employing contractile and electrically coupling embryonic cardiomyocytes (eCMs) into ischemic myocardium provoked significantly smaller infarcts with less adverse remodeling and improved cardiac function and long-term survival compared to transplantation of somatic cells (SMs and MSCs), thereby proving that a cardiomyocyte phenotype is important to restore myocardial function.Leonie E PaulisAlexandra M KleinAlexander GhanemTessa GeelenBram F CoolenMartin BreitbachKatrin ZimmermannKlaas NicolayBernd K FleischmannWilhelm RoellGustav J StrijkersPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e61510 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Leonie E Paulis Alexandra M Klein Alexander Ghanem Tessa Geelen Bram F Coolen Martin Breitbach Katrin Zimmermann Klaas Nicolay Bernd K Fleischmann Wilhelm Roell Gustav J Strijkers Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
description	<h4>Aims</h4>Controversy exists in regard to the beneficial effects of transplanting cardiac or somatic progenitor cells upon myocardial injury. We have therefore investigated the functional short- and long-term consequences after intramyocardial transplantation of these cell types in a murine lesion model.<h4>Methods and results</h4>Myocardial infarction (MI) was induced in mice (n = 75), followed by the intramyocardial injection of 1-2×10(5) luciferase- and GFP-expressing embryonic cardiomyocytes (eCMs), skeletal myoblasts (SMs), mesenchymal stem cells (MSCs) or medium into the infarct. Non-treated healthy mice (n = 6) served as controls. Bioluminescence and fluorescence imaging confirmed the engraftment and survival of the cells up to seven weeks postoperatively. After two weeks MRI was performed, which showed that infarct volume was significantly decreased by eCMs only (14.8±2.2% MI+eCM vs. 26.7±1.6% MI). Left ventricular dilation was significantly decreased by transplantation of any cell type, but most efficiently by eCMs. Moreover, eCM treatment increased the ejection fraction and cardiac output significantly to 33.4±2.2% and 22.3±1.2 ml/min. In addition, this cell type exclusively and significantly increased the end-systolic wall thickness in the infarct center and borders and raised the wall thickening in the infarct borders. Repetitive echocardiography examinations at later time points confirmed that these beneficial effects were accompanied by better survival rates.<h4>Conclusion</h4>Cellular cardiomyoplasty employing contractile and electrically coupling embryonic cardiomyocytes (eCMs) into ischemic myocardium provoked significantly smaller infarcts with less adverse remodeling and improved cardiac function and long-term survival compared to transplantation of somatic cells (SMs and MSCs), thereby proving that a cardiomyocyte phenotype is important to restore myocardial function.
format	article
author	Leonie E Paulis Alexandra M Klein Alexander Ghanem Tessa Geelen Bram F Coolen Martin Breitbach Katrin Zimmermann Klaas Nicolay Bernd K Fleischmann Wilhelm Roell Gustav J Strijkers
author_facet	Leonie E Paulis Alexandra M Klein Alexander Ghanem Tessa Geelen Bram F Coolen Martin Breitbach Katrin Zimmermann Klaas Nicolay Bernd K Fleischmann Wilhelm Roell Gustav J Strijkers
author_sort	Leonie E Paulis
title	Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
title_short	Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
title_full	Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
title_fullStr	Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
title_full_unstemmed	Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
title_sort	embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/eadcfda88b0e480e92d06df2a1ab06c2
work_keys_str_mv	AT leonieepaulis embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT alexandramklein embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT alexanderghanem embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT tessageelen embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT bramfcoolen embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT martinbreitbach embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT katrinzimmermann embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT klaasnicolay embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT berndkfleischmann embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT wilhelmroell embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival AT gustavjstrijkers embryoniccardiomyocytebutnotautologousstemcelltransplantationrestrictsinfarctexpansionenhancesventricularfunctionandimproveslongtermsurvival
_version_	1718422945972355072

Embryonic cardiomyocyte, but not autologous stem cell transplantation, restricts infarct expansion, enhances ventricular function, and improves long-term survival.

Ejemplares similares